‘Rubeosis capsulare’ is an uncommon condition of neovascularisation within the lens capsule and is not amenable to conventional treatment modalities. 1 Bevacizumab, a humanised monoclonal anti-VEGF ...

Icon Bioscience announced that melphalan intraocular injection, the company’s investigational product for the treatment of retinoblastoma, has been granted Orphan Drug Designation by the FDA. Icon’s ...

Repeat treatment with corticosteroid injections improved vision in people with persistent or recurrent uveitis-related macular edema better than two other therapies, according to results from a ...

SUNNYVALE, Calif., Jan. 3, 2013 -- Icon Bioscience, Inc., (IBI), a privately held biopharmaceutical company that specializes in the development and commercialization of novel ophthalmic ...

A new treatment for patients with a form of congenital retinal blindness has shown success in improving vision, according to results published today in Nature Medicine led by researchers at the Scheie ...

The analysis included 41 patients who were treated with 136 intravitreal aflibercept, 8mg, injections. HealthDay News — The incidence of mild intraocular inflammation (IOI) in the real world occurs ...

A panel of ophthalmologists defined points of consensus for suprachoroidal space injections based on current published evidence. IVT is the primary method of delivering therapeutics in the eye, ...

RGX-314 continues to be well-tolerated at all dose levels Long-term, durable treatment effect demonstrated over two years in Cohort 3 Mean improvement in vision (+14 letters) and stable retinal ...

A newly published clinical trial appeared in Nature Medicine on April 1. The trial was conducted on patients suffering from Leber congenital amaurosis, a rare and genetic eye disorder. One trial ...

NEWTON, Mass., November 25, 2025--(BUSINESS WIRE)--Inflammasome Therapeutics, a private, clinical-stage biotech company developing novel, first-in-class, dual inflammasome inhibitors for prevalent ...

Kalaris Therapeutics (KLRS) announced initial data from its Phase 1a single ascending dose trial of TH103, a fully humanized, recombinant fusion ...